<DOC>
	<DOCNO>NCT01656122</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic parameter ABC 3TC HIV-infected child young 18 year old body weight ≥ 14 kg .</brief_summary>
	<brief_title>Abacavir Lamivudine PK Children</brief_title>
	<detailed_description>Abacavir ( ABC ) nucleoside reverse transcriptase inhibitor ( NRTI ) continue good efficacy even patient resistant mutation NRTIs . ABC approve use child 3 month old . It prefer NRTI option second line treatment child World Health Organization guideline ( WHO ) . In US European guideline , ABC also recommend first line treatment . Published study support efficacy safety twice daily ABC . In HIV-infected child &lt; 12 year , ABC license twice-daily . However , ABC license either twice-daily once-daily HIV-infected adult child &gt; 12 year . In addition , ABC administer fix dose combination once-daily lamivudine ( 3TC ) , Kivexa , HIV-infected adult child &gt; 12 year . Lamivudine ( 3TC ) commonly use NRTI well tolerate approve young infant child component first second-line regimen guideline . Both once-daily twice-daily 3TC standard practice many treatment guideline although once-daily US FDA-approved age &gt; 12 year . The Thai Ministry Health pediatric HIV treatment guideline recommend either once- twice-daily treatment option child . The WHO currently recommend twice-daily 3TC dosing encourages pharmacokinetic study once-daily 3TC child . PK ABC 3TC African European child show similar PK parameter twice daily daily dosing . There data PK ABC Asian child study PK 3TC Thai child . Vanprapar et al . report data 42 Thai child weigh 6-30 kg participate cross-over PK study receive twice-daily dose generic fix dose combination tablet stavudine , 3TC , nevirapine liquid formulation drug . The 3TC exposure significantly high tablet formulation comparable historical data western adult child take branded tablet . Chokephaibulkit et al . report high 3TC exposure 41 Thai HIV-infected child 3TC tablet 3TC solution . There strong evidence indicate Asian patient , particularly Thais , high plasma concentration several ARVs compare Westerners . Genetic difference ethnicity may primary cause alter drug metabolism , result , different PK parameter . Higher drug concentration Thai adult show zidovudine , nevirapine , efavirenz , indinavir , lopinavir , atazanavir saquinavir . Such high ARV concentration also show Thai child nevirapine , indinavir , lopinavir saquinavir . There data Thai child ABC . Only two study evaluate 3TC concentration Thai child use twice-daily dosing . It conceivable Thai child may different PK profile ABC 3TC particularly once-daily dosing report African European child . In addition , use ABC 3TC provide opportunity Thai child benefit once-daily dose good long-term safety particularly favorable lipodystrophy lipid profile .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Have diagnosis HIV infection use ageappropriate test 2 . Age &lt; 18 year 3 . Body weight ≥ 14 kg 4 . Currently treat stable HAART within 30 day prior enrollment 5 . HIV RNA &lt; 50 copies/ml 6 . Have negative HLA B5701 currently ABCcontaining HAART tolerate regimen well 7 . Caregivers give write informed consent child age 7 year know HIV status give assent 1 . Child/Caretaker refuse participate study 2 . Has vomit diarrhea &gt; grade 3 ( DAIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 December 2004 , clarification date August 2009 ) within 30 day prior enrollment 3 . Has follow laboratory toxicity &gt; grade II accord division AIDS table grade severity adult pediatric adverse event within 30 day prior enrollment : SGPT Hemoglobin Creatinine 4 . Has current active HIVrelated infection 5 . Has significant medical problem would compromise study result investigator 's opinion 6 . Pregnancy 7 . Has history poor adherence ARV define less 80 % pill count history within 30 day prior enrollment 8 . Concomitant treatment drug know influence PK ABC ( ribavirin , ethanol methadone )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pharmacokinetic paramters</keyword>
	<keyword>abacavir</keyword>
	<keyword>lamuvidine</keyword>
	<keyword>HIV-infected child</keyword>
</DOC>